Notizie AIOM – anno XV n. 643

19 Settembre 2017

NCCN Guidelines to Include Categories of Preference

September 15, 2017 - The National Comprehensive Cancer Network® (NCCN®) has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Initially, Categories of Preference will be published ...
Leggi tutto

19 Settembre 2017

15 settembre 2017 – Monitoraggio della Spesa Farmaceutica Nazionale e Regionale (gennaio / maggio 2017)

19 Settembre 2017

FDA Approval Sought for Abiraterone Acetate for Early-Stage Metastatic Prostate Cancer

September 15, 2017 - A supplemental new drug application has been submitted for abiraterone acetate in combination with prednisone and androgen deprivation therapy (ADT) for high-risk patients with metastatic hormone-naïve prostate cancer (HNPC) or newly-diagnosed metastatic ...
Leggi tutto

15 Settembre 2017

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria ...
Leggi tutto

15 Settembre 2017

FDA Accepts Application for Rituximab Biosimilar

September 12, 2017 - The FDA has accepted a biologics license application (BLA) for the rituximab biosimilar (GP2013), according to Sandoz (Novartis), the company developing the treatment. If approved, rituximab biosimilar (GP2013) would be indicated for the hematologic ...
Leggi tutto

15 Settembre 2017

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial ...
Leggi tutto

15 Settembre 2017

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistantProstate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between these two drugs when used sequentially, but robust, prospective ...
Leggi tutto

15 Settembre 2017

Lo screening può salvarti la vita!

Cittadinanzattiva lancia una campagna informativa digital sui principali social network, con hashtag #nonaspettare, di supporto al programma nazionale di screening per il cancro alla mammella, al colon retto e alla cervice uterina. Obiettivo è quello di raggiungere ...
Leggi tutto

15 Settembre 2017

Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy

Despite existing evidence of a benefit associated with cisplatin-based adjuvant chemotherapy (AC) after radical cystectomy (RC) for chemotherapy-naive patients with pT3/T4 and/or pN+ urothelial carcinoma of the bladder (UCB), to our knowledge, no studies have addressed the ...
Leggi tutto

15 Settembre 2017

Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group

The frequency of capecitabine-related cardiotoxicity has been reported to be low but includes serious adverse events. We conducted a retrospective analysis of the incidence and severity of capecitabine-related cardiotoxicity in different regimens in the treatment of metastatic ...
Leggi tutto

LAVORIAMO CON

News

MEDICINA DI LABORATORIO, OLTRE IL 70% DELLE DECISIONI CLINICHE DIPENDE DALLE ANALISI. PRESENTATO IL PRIMO STUDIO NAZIONALE SULL’APPLICAZIONE DEL NUOVO NOMENCLATORE TARIFFARIO

TUMORI: “CNAO È CENTRO DI RIFERIMENTO MONDIALE NELL’ADROTERAPIA. A OGGI TRATTATI PIÙ DI 6.200 PAZIENTI”

MALATTIE AUTOIMMUNI: AL GIFFONI FILM FESTIVAL ARRIVA “PIÙ FORTE IO”. CON TENACIA E NUOVE TERAPIE POSSIBILE SUPERARE LE PATOLOGIE CRONICHE

L’OCULISTA: ANCHE IN ESTATE POSSIBILE FARSI OPERARE DI GLAUCOMA. PER PROTEGGERE GLI OCCHI BASTANO MASCHERINE, CAPPELLINI E OCCHIALI

MEDICINA DI LABORATORIO, I CLINICI ITALIANI RICONOSCIUTI TRA LE ECCELLENZE INTERNAZIONALI. “IL NOSTRO PAESE TRA I PROTAGONISTI DELL’EVOLUZIONE DELLA DIAGNOSTICA NEL MONDO”

TUMORE DELL’OVAIO, 1 DONNA SU 3 ASPETTA PIÙ DI UN ANNO PER LA DIAGNOSI. “NECESSARIO AUMENTARE L’ACCESSO AI CENTRI AD ALTO VOLUME, AL SUPPORTO PSICONCOLOGICO E ALL’INNOVAZIONE TERAPEUTICA”

TUMORE DEL SENO, IN ITALIA 950MILA DONNE VIVONO CON UNA DIAGNOSI. ROPI: ‘RACCOMANDATI ALMENO 150 MINUTI D’ATTIVITA’ FISICA ALLA SETTIMANA’

Notizie AIOM – anno XV n. 643

NCCN Guidelines to Include Categories of Preference

15 settembre 2017 – Monitoraggio della Spesa Farmaceutica Nazionale e Regionale (gennaio / maggio 2017)

FDA Approval Sought for Abiraterone Acetate for Early-Stage Metastatic Prostate Cancer

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

FDA Accepts Application for Rituximab Biosimilar

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistantProstate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

Lo screening può salvarti la vita!

Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy

Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group